You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Targets to Treatments: Evaluating the Ongoing Evolution in the Care of Cholangiocarcinoma

  • Authors: Ghassan K. Abou-Alfa, MD, MBA; Nilofer S. Azad, MD
  • CME / ABIM MOC Released: 11/5/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/15/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for hematology and oncology specialists.

The goal of this activity is to provide expert-level discussion on the late-stage agents in metastatic cholangiocarcinoma and improve the knowledge and competence of oncologists in integrating novel therapies into their practice through review of cases.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Ongoing clinical trial safety and efficacy data evaluating targeted therapies in the management of patients with metastatic cholangiocarcinoma
  • Have greater competence related to
    • Incorporating molecular testing into clinical practice to identify therapies in late-stage development that may benefit patients with metastatic cholangiocarcinoma with actionable mutations
    • Selecting targeted agents in eligible patients with metastatic cholangiocarcinoma


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Ghassan K. Abou-Alfa, MD, MBA

    Professor of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Disclosure: Ghassan K. Abou-Alfa, MD,MBA, has the following relevant financial relationships:
    Advisor or consultant for: Adicet; Alnylam; AstraZeneca; Autem; Bayer; BeiGene; Berry Genomics; Celgene; Cend; CytomX; Eisai; Eli Lilly; Exelixis; Flatiron; Genentech; Genoscience; Helio; Incyte Corporation; Ipsen; Legend Biotech; Merck, Nerviano; QED; Redhill; Rafael; Roche; Servier Pharmaceuticals; Silenseed; Sobi; Surface Oncology; Therabionic; Vector; Yiviva
    Speaker or a member of a speakers bureau for: Adicet; Alnylam; AstraZeneca; Autem; Bayer; BeiGene; Berry Genomics; Celgene; Cend; CytomX; Eisai; Eli Lilly; Exelixis; Flatiron; Genentech; Genoscience; Helio; Incyte Corporation; Ipsen; Legend Biotech; Merck, Nerviano; QED; Redhill; Rafael; Roche; Servier Pharmaceuticals; Silenseed; Sobi; Surface Oncology; Therabionic; Vector; Yiviva
    Grants for clinical research from: Arcus; Agios; AstraZeneca; BioNtech; Bristol Myers Squibb; Celgene; Flatiron; Genentech; Genoscience; Incyte Corporation; Polaris; Puma; QED; Roche; Silenseed; Yiviva

  • Nilofer S. Azad, MD

    Professor of Oncology
    Johns Hopkins University School of Medicine
    Cancer Genetics and Epigenetics Program
    Developmental Therapeutics Clinical Trials Program
    Johns Hopkins Sidney Kimmel Cancer Center
    Baltimore, Maryland

    Participation by Dr Azad does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Disclosures

    Disclosure: Nilofer S. Azad, MD, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca; Mirati; QED
    Grants for clinical research from: Array; Astex; Atlas; Bristol Myers Squibb; Celgene; Incyte Corporation; Intensity; Merck; Syndax; Taiho Oncology

Editor

  • Mihai Surducan, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Mihai Surducan, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Targets to Treatments: Evaluating the Ongoing Evolution in the Care of Cholangiocarcinoma

Authors: Ghassan K. Abou-Alfa, MD, MBA; Nilofer S. Azad, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 11/5/2021

Valid for credit through: 12/15/2022

processing....

Assessment Survey

Before you begin, please take this brief survey.

  • Print